Combination of antibody-drug conjugate and immune checkpoint inhibitor
NZ795245BActive Publication Date: 2026-09-29DAIICHI SANKYO CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ795245
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-09-25
- Filing Date
- 2017-12-11
- Publication Date
- 2026-09-29
- Estimated Expiration
- 2037-12-11
Smart Images

Figure 1_ABST
Abstract
A pharmaceutical composition and a treatment method, each of which is characterized in that an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, wherein the antibody-drug conjugate is formed by bonding a drug linker represented by formula (1) (wherein A represents an antibody-bonding position) to an antibody through a thioether bond; and a pharmaceutical composition and a treatment method, each of which is characterized in that the antibody-drug conjugate is contained and is also characterized by being used for the treatment of a disease that can be ameliorated through an anti-tumor immunity activation effect.
Need to check novelty before this filing date? Find Prior Art